Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Exp Neurol. 2017 Apr 12;293:144–158. doi: 10.1016/j.expneurol.2017.04.004

Figure 5.

Figure 5

Carrageenan-induced AMPAr trafficking is NMDA receptor dependent. (A) Pretreatment with MK801, an NMDA receptor antagonist, blocks inflammation –induced trafficking of GluA1 to the plasma membrane. (B) MK801 treatment had no affect on GluA2 at this time. Data is presented as mean±SEM, * n=4, p < 0.05, and *** p < 0.001